Akebia Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in September 2025. The company's executives will present at the Wells Fargo Healthcare Conference in Boston (September 3-5) and the H.C. Wainwright 27th Annual Global Investment Conference in New York (September 8-10).
Chief Financial and Chief Business Officer Erik Ostrowski and Chief Commercial Officer Nik Grund will lead both presentations. The Wells Fargo presentation is scheduled for September 4 at 8:00 AM EDT, while the H.C. Wainwright fireside chat will take place on September 8 at 12:00 PM EDT. Webcasts will be available through Akebia's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
On the day this news was published, AKBA gained 3.99%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025 in New York.
Wells Fargo Healthcare Conference
Erik Ostrowski, Chief Financial and Chief Business Officer, and Nik Grund, Chief Commercial Officer, will present on Thursday, September 4 at 8:00 AM EDT.
H.C. Wainwright Global Investment Conference
Mr. Ostrowski and Mr. Grund will participate in a fireside chat on Monday, September 8 at 12:00 PM EDT.
A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When is Akebia Therapeutics (AKBA) presenting at the Wells Fargo Healthcare Conference 2025?
Who will be presenting at Akebia's (AKBA) September 2025 investor conferences?
When is Akebia's (AKBA) presentation at the H.C. Wainwright Conference 2025?
How can investors access Akebia Therapeutics' (AKBA) conference presentations?
